
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Cancer Research UK"
Count: 276
Selected: 0
NCT ID | Title |
---|
NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations | ||
NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | ||
NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | ||
NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers | ||
NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | ||
NCT05722886 | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol | ||
NCT06045910 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | ||
NCT03096054 | A CR-UK Phase I Trial of LY3143921 | ||
NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | ||
NCT04908111 | A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 | ||
NCT02546921 | Phase I Study of MOv18 IgE | ||
NCT05272709 | TT-702 in Patients With Advanced Solid Tumours. | ||
NCT03371485 | AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer | ||
NCT05057013 | HMBD-001 in Advanced HER3 Positive Solid Tumours | ||
NCT03486730 | BT1718 in Patients With Advanced Solid Tumours. | ||
NCT04455815 | A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) | ||
NCT01791595 | A Phase I Trial of AZD3965 in Patients With Advanced Cancer | ||
NCT01586624 | A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1) | ||
NCT02761915 | A Phase I Trial of Anti-GD2 T-cells (1RG-CART) | ||
NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | ||
NCT02043899 | A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma | ||
NCT00985868 | AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors | ||
NCT01585701 | Phase I Study of AT13148, a Novel AGC Kinase Inhibitor | ||
NCT02540928 | AMG 319 in HPV Positive and Negative HNSCC | ||
NCT01800071 | A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma | ||
NCT01805375 | A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies | ||
NCT01668550 | A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours | ||
NCT01390571 | Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma | ||
NCT00755885 | Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer | ||
NCT00664781 | Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer | ||
NCT01222221 | Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | ||
NCT01098344 | MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery | ||
NCT01324115 | NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors | ||
NCT01561911 | A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment | ||
NCT01431664 | AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia | ||
NCT01233492 | Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme | ||
NCT01118611 | Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors | ||
NCT01147029 | GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy | ||
NCT01212887 | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | ||
NCT01147991 | Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer | ||
NCT01132599 | Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer | ||
NCT00989105 | Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer | ||
NCT00863733 | Study of DMXAA (Now Known as ASA404) in Solid Tumors | ||
NCT00749450 | Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer | ||
NCT00259844 | Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed | ||
NCT00104897 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma | ||
NCT00967954 | Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer | ||
NCT00974792 | Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma | ||
NCT00959231 | Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease | ||
NCT00958854 | Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma |